Research Paper Volume 13, Issue 5 pp 6506—6524

Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients

Adjusted multivariate risk of genetic variant in the elderly for subsequent one-year adverse events. (A) Poor metabolizer of CYP2C19 (B) TT of P2Y12 platelet adenosine 5′-diphosphate receptor gene G52T polymorphism. Hazard ratio was adjusted for sex, hypertension, diabetes mellitus, previous history of myocardial infarction, previous history of percutaneous coronary intervention, congestive heart failure, chronic kidney disease, current smoking status, anemia, clinical presentation to acute coronary syndrome, genomic variations (CYP2C19, P2Y12, PON1, and ABCB1), duration of dual antiplatelet therapy, multivessel involvement, minimal stent size, and total stent length. BARC, Bleeding Academic Research Consortium; HR, hazard ratio.

Figure 3. Adjusted multivariate risk of genetic variant in the elderly for subsequent one-year adverse events. (A) Poor metabolizer of CYP2C19 (B) TT of P2Y12 platelet adenosine 5′-diphosphate receptor gene G52T polymorphism. Hazard ratio was adjusted for sex, hypertension, diabetes mellitus, previous history of myocardial infarction, previous history of percutaneous coronary intervention, congestive heart failure, chronic kidney disease, current smoking status, anemia, clinical presentation to acute coronary syndrome, genomic variations (CYP2C19, P2Y12, PON1, and ABCB1), duration of dual antiplatelet therapy, multivessel involvement, minimal stent size, and total stent length. BARC, Bleeding Academic Research Consortium; HR, hazard ratio.